Citations

Mayo Clinic

Showing 10 of 108551 citations.

Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit β-2 Immunoglobulin-G–Associated Autoimmune Ataxia
Kothapalli, Naga Pradyumna, McKeon, Andrew , Dubey, Divyanshu , Chompoopong, Pitcha , McKeon, Andrew , Dubey, Divyanshu

Neurology | March 15, 2024 | Volume: 102 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000209257 | PMID 38489556 Get It

Can MRI Replace Nasopharyngoscopy in the Evaluation of Velopharyngeal Insufficiency?
Chee-Williams, Jessica L. , Perry, Jamie L. , Snodgrass, Taylor D. , Singh, Davinder , Temkit, M’hamed , Sitzman, Thomas J. , Sitzman, Thomas J , Singh, Davinder J , Chee-Williams, Jessica L , Snodgrass, Taylor , Perry, Jamie L

The Cleft Palate Craniofacial Journal | March 15, 2024 | Volume: 62 | Issue: 7 | Pages: 1093-1102

10.1177/10556656241239459 | PMID 38490221 Get It

Objective To investigate whether flexible nasopharyngoscopy, when performed in addition to magnetic resonance imaging (MRI), influences the type of surgery selected or success of surgery in patients with velopharyngeal insufficiency (VPI). Design Cohort study. Setting A metropolitan children's hospital. Patients Patients with non-syndromic, repaired cleft palate presenting for management of VPI. Interventions MRI and nasopharyngoscopy or MRI alone for preoperative imaging of the velopharyngeal mechanism. Main Outcome Measures (1) Surgical selection and (2) resolution of hypernasality. All speech, MRI, and nasopharyngoscopy measurements were performed by raters blinded to patients’ medical and surgical history. Results Of the 25 patients referred for nasopharyngoscopy, 76% completed the exam. Of the 41 patients referred for MRI, the scan was successfully completed by 98% of patients. Completion of nasopharyngoscopy was significantly (p=0.01) lower than MRI. Surgical selection did not significantly differ (p=0.73) between the group receiving MRI and nasopharyngoscopy and the group receiving MRI alone, nor was there a significant difference between these groups in the proportion of patients achieving resolution of hypernasality postoperatively (p=0.63). Percent total velopharyngeal closure assessments on nasopharyngoscopy and MRI were strongly correlated (r=0.73). Conclusions In patients receiving MRI as part of their preoperative VPI evaluation, the addition of nasopharyngoscopy did not result in a difference in surgical selection or resolution of hypernasality. Routine inclusion of nasopharyngoscopy may not be necessary for the evaluation of velopharyngeal anatomy when MRI is available.
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction
Suda, Masayoshi , Paul, Karl H , Tripathi, Utkarsh , Tchkonia, Tamar , Kirkland, James L. , Tchkonia, T , Kirkland, James L , Suda, Masayoshi , Minamino, Tohru

Endocrine Reviews | March 15, 2024 | Volume: 45 | Issue: 5 | Pages: 655-675

10.1210/endrev/bnae010 | PMID 38500373 Get It

Abstract Multiple changes occur in hormonal regulation with aging and across various endocrine organs. These changes are associated with multiple age-related disorders and diseases. A better understanding of responsible underling biological mechanisms could help in the management of multiple endocrine disorders over and above hormone replacement therapy (HRT). Cellular senescence is involved in multiple biological aging processes and pathologies common in elderly individuals. Cellular senescence, which occurs in many older individuals but also across the lifespan in association with tissue damage, acute and chronic diseases, certain drugs, and genetic syndromes, may contribute to such endocrine disorders as osteoporosis, metabolic syndrome, and type 2 diabetes mellitus. Drugs that selectively induce senescent cell removal, “senolytics,”, and drugs that attenuate the tissue-destructive secretory state of certain senescent cells, “senomorphics,” appear to delay the onset of or alleviate multiple diseases, including but not limited to endocrine disorders such as diabetes, complications of obesity, age-related osteoporosis, and cancers as well as atherosclerosis, chronic kidney disease, neurodegenerative disorders, and many others. More than 30 clinical trials of senolytic and senomorphic agents have already been completed, are underway, or are planned for a variety of indications. Targeting senescent cells is a novel strategy that is distinct from conventional therapies such as HRT, and thus might address unmet medical needs and can potentially amplify effects of established endocrine drug regimens, perhaps allowing for dose decreases and reducing side effects.
How Real Are the Effects of Virtual Reality in Decreasing Acute Pain?
D’Souza, Ryan S. , YaDeau, Jacques T. , D'Souza, Ryan S , Shanthanna, Harsha , Johnson, Rebecca L.

Anesthesia & Analgesia | March 15, 2024 | Volume: 138 | Issue: 4 | Pages: 746-750

10.1213/ane.0000000000006698 | PMID 38489794 Get It

CO 2 cerebrovascular reactivity measured with CBF-MRI in older individuals: Association with cognition, physical function, amyloid and tau proteins
Li, Yang , Yaşar, Sevil , Rosenberg, Paul B. , Jiang, Dengrong , Kalyani, Rita R. , Hazel, Kaisha , Pottanat, George , Xu, Cuimei, Pillai, Jay J. , Albert, Marilyn, Jiang, Dengrong , Lu, Hanzhang , Pillai, Jay J , Sur, Sandeepa , Lin, Zixuan , Moghekar, Abhay , Hou, Xirui , Liu, Peiying , Lu, Hanzhang

Journal of Cerebral Blood Flow & Metabolism | March 15, 2024 | Volume: 44 | Issue: 9 | Pages: 1618-1628

10.1177/0271678x241240582 | PMID 38489769 Get It

Vascular pathology is the second leading cause of cognitive impairment and represents a major contributing factor in mixed dementia. However, biomarkers for vascular cognitive impairment and dementia (VCID) are under-developed. Here we aimed to investigate the potential role of CO2 Cerebrovascular Reactivity (CVR) measured with phase-contrast quantitative flow MRI in cognitive impairment and dementia. Forty-five (69 ± 7 years) impaired (37 mild-cognitive-impairment and 8 mild-dementia by syndromic diagnosis) and 22 cognitively-healthy-control (HC) participants were recruited and scanned on a 3 T MRI. Biomarkers of AD pathology were measured in cerebrospinal fluid. We found that CBF-CVR was lower (p = 0.027) in the impaired (mean±SE, 3.70 ± 0.15%/mmHg) relative to HC (4.28 ± 0.21%/mmHg). After adjusting for AD pathological markers (Aβ42/40, total tau, and Aβ42/p-tau181), higher CBF-CVR was associated with better cognitive performance, including Montreal Cognitive Assessment, MoCA (p = 0.001), composite cognitive score (p = 0.047), and language (p = 0.004). Higher CBF-CVR was also associated with better physical function, including gait-speed (p = 0.006) and time for five chair-stands (p = 0.049). CBF-CVR was additionally related to the Clinical-Dementia-Rating, CDR, including global CDR (p = 0.026) and CDR Sum-of-Boxes (p = 0.015). CBF-CVR was inversely associated with hemoglobin A1C level (p = 0.017). In summary, CBF-CVR measured with phase-contrast MRI shows associations with cognitive performance, physical function, and disease-severity, independent of AD pathological markers.
Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019: Serologic Testing
Hayden, Mary K. , Mikati, Ibrahim K El , Hanson, Kimberly E. , Lee, Francesca , Loeb, Mark , Morgan, Daniel J., Ta’ani, Omar Al , Nazzal, Jamil, Iqneibi, Shahad , Falck–Ytter, Yngve , Bhimraj, Adarsh , Hanson, Kimberly , Englund, Janet A. , Humphries, Romney M. , Patel, Robin , Amarin, Justin Z. , Sultan, Shahnaz , Morgan, Rebecca L. , Murad, M. Hassan , Mustafa, Reem A

Clinical Infectious Diseases | March 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciae121 | PMID 38489670 Get It

Abstract Background The role of serologic testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved during the pandemic as seroprevalence in global populations has increased. The Infectious Diseases Society of America convened an expert panel to perform a systematic review of the coronavirus disease 2019 (COVID-19) serology literature and construct updated best practice guidance related to SARS-CoV-2 serologic testing. This guideline is an update to the fourth in a series of rapid, frequently updated COVID-19 guidelines developed by the Infectious Diseases Society of America. Objective To develop evidence-based recommendations and identify unmet research needs pertaining to the use of anti–SARS-CoV-2 antibody tests for diagnosis, decisions related to vaccination and administration of monoclonal antibodies or convalescent plasma in immunocompromised patients, and identification of a serologic correlate of immunity. Methods A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature reviewed, identified, and prioritized clinical questions related to the use of SARS-CoV-2 serologic tests. Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of evidence and make testing recommendations. Results The panel recommends against serologic testing to diagnose SARS-CoV-2 infection in the first 2 weeks after symptom onset (strong recommendations, low certainty of evidence). Serologic testing should not be used to provide evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly negative nucleic acid amplification test results (strong recommendation, very low certainty of evidence). Serologic testing may assist with the diagnosis of multisystem inflammatory syndrome in children (strong recommendation, very low certainty of evidence). To seek evidence for prior SARS-CoV-2 infection, the panel suggests testing for immunoglobulin G (IgG), IgG/IgM, or total antibodies to nucleocapsid protein 3 to 5 weeks after symptom onset (conditional recommendation, low certainty of evidence). In individuals with previous SARS-CoV-2 infection or vaccination, the panel suggests against routine serologic testing given no demonstrated benefit to improving patient outcomes (conditional recommendation, very low certainty of evidence). The panel acknowledges further that a negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy. Conclusions The high seroprevalence of antibodies against SARS-CoV-2 worldwide limits the utility of detecting anti-SARS CoV-2 antibody. The certainty of available evidence supporting the use of serology for diagnosis was graded as very low to low. Future studies should use serologic assays calibrated to a common reference standard.
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Patel, Keyur , Asrani, Sumeet K. , Fiel, Maria Isabel , Levine, Deborah , Leung, Daniel H. , Duarte‐Rojo, Andrés , Dranoff, Jonathan A. , Nayfeh, Tarek , Hasan, Bashar , Alsawaf, Yahya , Saadi, Samer , Majzoub, Abdul M., Ding, Jingyi , Sofiyeva, Nigar , Sterling, Richard K. , Taddei, Tamar H , Alsawaf, Yahya , Saadi, Samer , Majzoub, Abdul Mounaem, Manolopoulos, Apostolos , Alzuabi, Muayad , Ding, Jingyi , Sofiyeva, Nigar , Murad, Mohammad H, Alsawas, Mouaz , Rockey, Don C , Sterling, Richard K , Asrani, Sumeet K , Duarte-Rojo, Andres , Nayfeh, Tarek , Dranoff, Jonathan A , Fiel, Maria Isabel , Levine, Deborah , Hasan, Bashar , Manolopoulos, Apostolos , Murad, M. Hassan , Alsawas, Mouaz , Rockey, Don C.

Hepatology | March 15, 2024 | Volume: 81 | Issue: 1 | Pages: 358-379

10.1097/hep.0000000000000842 | PMID 38489517 Get It

Background and Aims: Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4), as compared to biopsy in chronic liver disease. Approach and Results: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022. Two independent reviewers selected 286 studies with 103,162 patients. The most frequently identified studies included the simple aspartate aminotransferase-to-platelet ratio index and fibrosis (FIB)-4 markers (with low-to-moderate risk of bias) in HBV and HCV, HIV-HCV/HBV coinfection, and NAFLD. Positive (LR+) and negative (LR−) likelihood ratios across direct and indirect biomarker tests for HCV and HBV for F2-4, F3-4, or F4 were 1.66–6.25 and 0.23–0.80, 1.89–5.24 and 0.12–0.64, and 1.32–7.15 and 0.15–0.86, respectively; LR+ and LR− for NAFLD F2-4, F3-4, and F4 were 2.65–3.37 and 0.37–0.39, 2.25–6.76 and 0.07–0.87, and 3.90 and 0.15, respectively. Overall, the proportional odds ratio indicated FIB-4 <1.45 was better than aspartate aminotransferase-to-platelet ratio index <0.5 for F2-4. FIB-4 >3.25 was also better than aspartate aminotransferase-to-platelet ratio index >1.5 for F3-4 and F4. There was limited data for combined tests. Conclusions: Blood-based biomarkers are associated with small-to-moderate change in pretest probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV coinfection, and NAFLD, with limited comparative or combination studies for other chronic liver diseases.
Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline
Rockey, Don C. , Duarte‐Rojo, Andrés , Patel, Keyur , Nayfeh, Tarek , Alsawaf, Yahya , Saadi, Samer , Malandris, Konstantinos , Sterling, Richard K. , Duarte-Rojo, Andres , Hasan, Bashar , Sterling, Richard K , Nayfeh, Tarek , Rockey, Don C , Alsawaf, Yahya , Saadi, Samer , Alsawas, Mouaz , Levine, Deborah, Asrani, Sumeet K. , Hasan, Bashar , Murad, M. Hassan

Hepatology | March 15, 2024 | Volume: 81 | Issue: 3 | Pages: 1086-1104

10.1097/hep.0000000000000841 | PMID 38489516 Get It

Background and Aims: Portal hypertension is a serious complication of cirrhosis, which leads to life-threatening complications. HVPG, a surrogate of portal pressure, is the reference standard test to assess the severity of portal hypertension. However, since HVPG is limited by its invasiveness and availability, noninvasive liver disease assessments to assess portal pressure, especially clinically significant portal hypertension (CSPH), are needed. Approach and Results: We conducted a systematic review of Ovid MEDLINE(R) Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus from each database’s inception to April 22, 2022. We included only studies in English that examined ≥50 patients in single liver disease etiologies, which compared noninvasive tests (blood and/or imaging) to HVPG for predicting clinically significant portal hypertension (CSPH; defined as HVPG ≥ 10 mm Hg) in patients with chronic liver disease. Outcomes included measures of diagnostic test accuracy. Additionally, a narrative review of studies not eligible for the systematic review is also provided. Nine studies with 2492 patients met the inclusion criteria. There was substantial heterogeneity with regard to liver disease studied and cutoff values used to detect CSPH. Blood-based tests, including aspartate-to-platelet ratio index (APRI) (56% sensitivity and 68% specificity) and FIB-4 (54% sensitivity and 73% specificity) had low accuracy measures. Imaging-based tests (transient elastography and shear wave elastography detection of liver stiffness measurement [LSM]) had better accuracy but also had substantial variation; at 15 kPa, TE sensitivity was 90%–96% and specificity was 48%–50%, while at 25 kPa, its sensitivity and specificity were 57%–85% and 82%–93%, respectively. The narrative review suggested that imaging-based tests are the best available noninvasive liver disease assessment to detect CSPH; CSPH is highly unlikely to be present at an LSM ≤15 kPa and likely to be present at an LSM ≥25 kPa. Conclusions: While imaging-based noninvasive liver disease assessment appeared to have higher accuracy than blood-based tests to detect CSPH, only 9 studies fit the a priori established inclusion criteria for the systematic review. In addition, there was substantial study heterogeneity and variation in cutoffs for LSM to detect CSPH, limiting the ability to establish definitive cutoffs to detect CSPH.